InterMune Divests Declining Actimmune® to Focus on Esbriet®
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 5 (Table of Contents)
Published: 28 May-2012
DOI: 10.3833/pdr.v2012.i5.1746 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
InterMune has agreed to sell the rights to Actimmune® (interferon gamma-1b), which is approved for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis, to Vidara Therapeutics International for US$55 M in cash plus royalties over 2 years...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS